

# Yellow fever vaccine dose-response study

<b>Submission date</b> 28/11/2008	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 03/12/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/02/2013	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Reinaldo Martins

**Contact details**  
Av. Brasil 4365  
Manguinhos  
Rio de Janeiro  
Brazil  
21040-900

## Additional identifiers

**Protocol serial number**  
Asclin/003/2008

## Study information

**Scientific Title**  
Dose-response study of 17DD yellow fever vaccine produced by Bio-Manguinhos/Fiocruz

**Study objectives**  
Yellow fever vaccine on lower doses is effective and safe.

**Ethics approval required**  
Old ethics approval format

## **Ethics approval(s)**

Ethics Committee of Instituto de Pesquisa Clínica Evandro Chagas gave approval on the 10th November 2008 (ref: 0038.0.009.000-08)

## **Study design**

Double-blind randomised controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Yellow fever vaccination

## **Interventions**

Vaccination with one dose (subcutaneously [sc]) of yellow fever vaccine in current use or in five decreasing dilutions, and a placebo (placebo will receive vaccine as soon as possible):

Reference vaccine (in current use): approximately 60,000 PFU (approximately 12,000 MLD50)

Arm 1: approximately 20,000 PFU (approximately 4,000 MLD50)

Arm 2: approximately 6,667 PFU (approximately 1,300 MLD50)

Arm 3: approximately 2,222 PFU (approximately 450 MLD50)

Arm 4: approximately 740 PFU (approximately 150 MLD50)

Arm 5: approximately 246 PFU (approximately 50 MLD50)

Arm 6: placebo

Those who do not become protected by vaccination and the placebo group will receive one dose of the reference vaccine. Volunteers will be followed up for a month after vaccination. One year after vaccination there will be another blood collection, for evaluation of duration of immunity.

## **Intervention Type**

Drug

## **Phase**

Not Specified

## **Drug/device/biological/vaccine name(s)**

17DD yellow fever vaccine

## **Primary outcome(s)**

Neutralising antibodies: seroconversion and titre, during 30 days after vaccination

## **Key secondary outcome(s)**

1. Reactogenicity, measured with blood chemistry before vaccination, 5 days and 30 days after vaccination

2. Frequency of viraemia, evaluated 5 days after vaccination

3. Duration of immunity, measured 30 days after vaccination and one year later (9 - 15 months is acceptable)

**Completion date**

01/09/2010

## Eligibility

**Key inclusion criteria**

1. Adult men
2. Aged 18 - 30 years old
3. Healthy
4. Agree to participate after reading and understanding Free and Informed Consent Form

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

30 years

**Sex**

Male

**Key exclusion criteria**

1. Prior vaccination against yellow fever
2. Female
3. Use of immunosuppressor drugs in the last 12 months
4. Personal history of autoimmune diseases
5. Personal history of thymus diseases
6. Personal history of anaphylactic reactions to foods, drugs or vaccines
7. Personal history of allergy to eggs, erythromycin, canamycin or gelatin
8. Persons who received immunoglobulin, blood transfusions or blood derivatives in the last 12 months
9. Persons who received live virus vaccines or cholera vaccine in the last 30 days or who plan to receive them in the following 30 days after yellow fever vaccination

**Date of first enrolment**

01/03/2009

**Date of final enrolment**

01/09/2010

## Locations

## Countries of recruitment

Brazil

## Study participating centre

Av. Brasil 4365

Rio de Janeiro

Brazil

21040-900

## Sponsor information

### Organisation

Bio-Manguinhos/Fiocruz (Brazil)

### ROR

<https://ror.org/05gj5j117>

## Funder(s)

### Funder type

Research organisation

### Funder Name

Foundation for Scientific and Technological Development in Health (Fundação para o Desenvolvimento Científico e Tecnológico em Saúde [FIOTEC])/Oswaldo Cruz Foundation (Fundacio Oswaldo Cruz [Fiocruz]) (Brazil)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/04/2013		Yes	No